

SCIENTIFIC PROGRAM

SCIENTIFIC PLANNING COMMITTEE

CO-CHAIRS


Pier Francesco Ferrucci – Istituto Europeo di Oncologia, Milano, IT
Christoph Huber – Association for Cancer Immunotherapy, Mainz, DE
Arlene Sharpe - Harvard Medical School, Boston, MA, USA
Padmanee Sharma - MD Anderson Cancer Center, Houston, TX, USA

COMMITTEE

Mustafa Diken - Johannes Gutenberg University, Mainz, DE
Marina Garassino – University of Chicago, Chicago, IL, USA
Susan Kaech – Salk Institute for Biological Studies, La Jolla, CA, USA
Nir Hacohen, Harvard Medical School, MA, USA
Paola Nisticò – Regina Elena National Cancer Institute, Roma, IT
Pamela Ohashi – University of Toronto, Toronto, CAN
Catherine Sautès-Fridman – Paris Descartes University, Paris, FR
Andrea Schietinger – Sloan Kettering Institute, New York, NY, USA
Özlem Türeci - BioNTech, Mainz, DE
Cassian Yee - MD Anderson Cancer Center, Houston TX, USA
Laurence Zitvogel – Gustave Roussy Institute, Villejuif, FR

LOCAL ORGANISING COMMITTEE

Paola Allavena - Humanitas Research Hospital, Milano
Paolo Ascierto – Istituto Nazionale Tumori Fondazione G. Pascale, Napoli
Matteo Bellone – San Raffaele Scientific Institute, Milano
Vincenzo Bronte – Istituto Oncologico Veneto, Padova
Giulia Casorati – San Raffaele Scientific Institute, Milano
Anna Mondino – San Raffaele Scientific Institute, Milano
Vincenzo Russo – San Raffaele Scientific Institute, Milano
Antonio Sica – Humanitas Research Hospital, Milano
Claudio Tripodo – University of Palermo, Palermo



Day 1 - Wednesday, September 20, 2023

1:45 – 2:00 pm

Welcome

Pier Francesco Ferrucci – Italian Network for Cancer Biotherapy - NIBIT, (Italy)

Christoph Huber – European Network for Cancer Immunotherapy - ENCI, (Germany)

2:00 – 2:40 pm

ENCI-AIRC Lecture

Jim Allison – The University of Texas MD Anderson Cancer Centre (USA)
Immune Checkpoint Blockade in Cancer Therapy: historical perspective, new opportunities, and prospects for cures

Chair: Christoph Huber – European Network for Cancer Immunotherapy - ENCI (Germany)

2:45 – 4:15 pm

Session 1: With a little help from my friends: innate immune cells and stromal cells in the tumor microenvironment

Chairs: Lisa Coussens, Paola Allavena

2:45 – 3:10 pm

Lisa Coussens - Knight Cancer Institute (USA)

Immune Vulnerabilities in Solid Tumors: Leukocyte Communication Networks Regulate Neoplastic Progression and Response to Therapy

3:10 – 3:35 pm

Eric Vivier - Innate Pharma, Paris Saclay Cancer Cluster Marseille (France)

Harnessing Innate Immunity in Cancer Therapy

3:35 – 4:00 pm

Neta Erez - Tel Aviv University (Israel)

Stromal and immune plasticity shape the metastatic microenvironment

4:00 – 4:15 pm

Renato Ostuni* - Vita-Salute San Raffaele University (Italy)

IL-1 β + macrophages fuel pathogenic inflammation in pancreatic cancer

4:15 – 4:45 pm

Break

4:45 – 6:30 pm

Session 2: Deranged T and B cells within the tumor microenvironment

Chairs: Andrea Schietinger, Paola Nisticò

4:45 – 5:10 pm


Catherine Sautès-Fridman - University Paris Cité (France)

TLS and B cells in the immunotherapy response

5:10 – 5:35 pm

Andrea Schietinger - Sloan Kettering Institute (USA)


Intratumoral CD4 T cells: empowering CD8 T cells to eliminate tumors



- 5:35 – 6:00 pm **Yifat Merbl** - Weizmann Institute (Israel)
Proteasomal profiling: From global views of degradation to novel mechanisms of anti-tumor immunity
- 6:00 – 6:15 pm **Ludovic Martinet*** - Université Toulouse III-Paul Sabatier – INSERM - CNRS (France)
TCR-independent CD137 (4-1BB) signaling promotes CD8+ exhausted T cell proliferation and terminal differentiation
- 6:15 – 6:30 pm **Simone Park*** - University of Pennsylvania (USA)
Nonreciprocal plasticity and divergent development of tissue resident memory and exhausted CD8+ T cells
- 6:30 – 7:10 pm **William B. Coley Lecture**
Tak Wah Mak – University of Toronto (Canada)
Ni Miikana: The Path Forward


Chair: Jill O'Donnell-Tormey - Cancer Research Institute Chief Executive Officer and Director of Scientific Affairs (USA)
- 7:10 – 8:30 pm** **Welcome Reception**

*Short talk from proffered abstract



Day 2 - Thursday, September 21, 2023

- 8:30 – 10:15 am** **Session 3: The earlier the better: neoadjuvant immunotherapy against cancer**
Chairs: Christian Blank, Pier Francesco Ferrucci
- 8:30 – 8:55 am** **Padmanee Sharma** – MD Anderson Cancer Center (USA)
Immune Checkpoint Therapy: Identifying Mechanisms of Response and Resistance
- 8:55 – 9:20 am** **Christian Blank** – The Netherlands Cancer Institute (The Netherlands)
Neoadjuvant Immunotherapy – next steps towards total personalization
- 9:20 – 9:45 am** **Tina Cascone** – MD Anderson Cancer Center (USA)
Advances in neoadjuvant and perioperative immunotherapy for lung cancer
- 9:45 – 10:00 am** **Giuseppina Arbore*** – Vita-Salute San Raffaele University (Italy)
Immune determinants of response to neoadjuvant chemotherapy in esophageal adenocarcinoma
- 10:00 – 10:15 am** **Mercedes Machuca-Ostos*** – The Netherlands Cancer Institute (The Netherlands)
Early and late T cell dynamics upon neoadjuvant immune checkpoint blockade in cutaneous squamous cell carcinoma
- 10:15 – 10:45 am** **Break**
- 10:45 – 12:30 pm** **Round table 1: Harnessing immunotherapy against breast cancer**
Chairs: Silvia Formenti, Luis De la Cruz Merino
- 10:45 – 11:10 am** **Marleen Kok** – The Netherlands Cancer Institute (The Netherlands)
Improving immunotherapy for breast cancer patients
- 11:10 – 11:35 am** **Fatima Mehta Grigoriou** – Institut Curie (France)
Mapping stromal heterogeneity in breast cancer
- 11:35 – 12:00 am** **Silvia Formenti** – Weill Cornell Medicine (USA)
Adapting radiotherapy to immunotherapy
- 12:00 – 12:15 pm** **Nir Ben Chetrit*** – Weill Cornell Medicine (USA)
Harnessing innate immunity for immune oncology in breast cancer
- 12:15 – 12:30 pm** **Emanuela Romano*** – Institut Curie (France)
Tissue resident CD8+ T cell clonal expansion in triple negative breast cancer is associated with response to immunotherapy – exploratory biomarker study from the synergy trial



12:30 – 2:00 pm **Lunch and Poster Session A and Exhibits**

1:00 – 2:00 pm

Meet the Editor Session

Xin (Cindy) Sun – *Journal of Experimental Medicine*

Paolo Ascierto – *Annals of Oncology*

Karen Honey – *Cancer Immunology Research*

2:00 – 2:40 pm

Pezcoller Lecture

Alberto Mantovani – Humanitas Research Institute (Italy)

Innate Immunity, Inflammation and Cancer: double edged swords

Chairmen: Enzo Galligioni, President Pezcoller Foundation (Italy)

Mario Paolo Colombo, Istituto Nazionale Tumori (Italy)

2:45 – 4:30 pm

Round table 2: Lung cancer at the forefront of cancer immunotherapy

Chairs: Sergio Quezada, Marina Garassino

2:45 – 3:10 pm

Marina Garassino – University of Chicago (USA)

Beyond PD-L1 in NSCLC

3:10 – 3:35 pm

Sergio Quezada – Achilles Therapeutics/ UCL Cancer Institute (UK)

Targeting Clonal Neoantigens in NSCLC

3:35 – 4:00 pm

Diether Lambrechts – KU Leuven Center for Cancer Biology (Belgium)

Unraveling Tumor Immune responses during checkpoint immunotherapy using single-cell and spatial technologies

4:00 – 4:15 pm

Daniela Cerezo-Wallis* – Yale University (USA)

Cancer sculpts granulopoiesis to generate tumor-supportive neutrophils


4:15 – 4:30 pm

Edgar Gonzalez-Kozlova* – Icahn School of Medicine, Mount Sinai (USA)

Improper priming of tumor antigen-specific human CD4+ T cells leads to a dysfunctional state in immunotherapy-treated cancer patients


4:30 – 5:00 pm

Break




- 5:00 – 6:30 pm** **Session 4: Technologies, technologies, technologies: we need more**
Chairs: Nir Hacohen, Cassian Yee
- 5:00 – 5:25 pm **Nir Hacohen** – Harvard Medical School (USA)
Spatial Organization of the Immune Response in Tumors
- 5:25 – 5:50 pm **Aaron Newman** – Stanford Cancer Institute (USA)
Big data approaches for immuno-oncology
- 5:50 – 6:15 pm **Joakim Lundeberg** - KTH Royal Institute of Technology (Sweden)
The cancer ecosystems captured by spatially resolved omics
- 6:15 – 6:30 pm **Payal Watchmaker** * – University of California San Francisco (USA)
Priming of synnotch car T cells via CNS-specific antigen allows spatial and temporal regulation of car expression, persistence of T cells in the CNS, resulting in the complete and sustained eradication of aggressive glioblastoma
- 6:30 – 6:45 pm **Arja Ray** * – University of California San Francisco (USA)
Identification of potent effector CD8 T cells in tumors

*Short talk from proffered abstract



Day 3 – Friday, September 22, 2023

- 8:30 – 10:30 am** **Round table 3: How to overcome resistance of poorly sensitive tumors to immunotherapy**
Chairs: Mustafa Diken, Vincenzo Bronte
- 8:30 – 8:55 am **Andrea Alimonti** – Università della Svizzera Italiana (Switzerland)
Targeting senescent tumors and immune cells for effective cancer therapy
- 8:55 – 9:20 am **Vincenzo Bronte** – Istituto Oncologico Veneto (Italy)
The cold immune environment in pancreatic cancer
- 9:20 – 9:45 am **Özlem Türeci** – BioNTech (Germany)
mRNA-based immunotherapies
- 9:45 – 10:00 am **Chiara Falcomatà*** – Icahn School of Medicine at Mount Sinai (USA)
Identifying mechanisms of tumor immune composition control in pancreatic cancer subtypes
- 10:00 – 10:15 am **Tobias Wertheimer *** – University of Zurich (Switzerland)
IL-23 stabilizes an effector treg program in the tumor microenvironment
- 10:15 – 10:30 am **Enrico Lugli*** – IRCCS Humanitas Research Hospital (Italy)
NaCl primes CD8+ T cells for enhanced effector function in cancer immunotherapy
- 10:30 – 11:00 am** **Break**
- 11:00 – 12:45 pm** **Round table 4: Melanoma immunotherapy – learning from failure and Success**
Chairs: Tom Gajewski, Pier Francesco Ferrucci
- 11:00 – 11:25 am **Tom Gajewski** – The University of Chicago (USA)
Improving immunotherapy efficacy by understanding mechanisms of resistance
- 11:25 – 11:50 am **Paolo Ascierto** – National Tumour Institute “Fondazione G. Pascale” (Italy)
Combination strategy to overcome resistance
- 11:50 – 12:15 pm **Jeffrey Weber** – NYU Langone New York (USA)
Neo- antigen vaccines with checkpoint inhibition: a novel adjuvant strategy for melanoma and other cancers.
- 12:15 – 12:30 pm **Clea Dziagwa*** – University of Liège (Belgium)
KEOPS complex links TRNA modification to T cell activation in melanoma
- 12:30 – 12:45 pm **Joanna Pozniak*** – VIB KULeuven (Belgium)
The increasing complexity of the melanoma transcriptomic landscape and its changes under immunotherapy



12:45 – 2:00 pm Lunch and Poster Session B and Exhibits

2:00 – 4:10 pm Session 5: Metabolic barriers to cancer immunotherapy

Chairs: Guido Kroemer, Vincenzo Russo


- 2:00 – 2:25 pm **Guido Kroemer** – Université de Paris (France)
Improving the cancer-immune crosstalk by caloric restriction mimetics
- 2:25 – 2:50 pm **Susan Kaech** – Salk Institute for Biological Studies (USA)
Nutritional influence on T cell exhaustion
- 2:50 – 3:15 pm **Antonio Sica** – University of Eastern Piedmont (Italy)
Metabolic dysregulation of myelopoiesis in cancer
- 3:15 – 3:40 pm **Greg Delgoffe** – University of Pittsburgh (USA)
Metabolic inputs and outputs of exhausted T cells in cancer
- 3:40 – 3:55 pm **Teresa Manzo*** – European Institute of Oncology (Italy)
Linoleic acid potentiates CD8+ T cell metabolic fitness and anti-tumor immunity

4:00 – 4:30 pm Break

4:30 – 6:25 pm Session 6: Determinants of response to immunotherapy

Chairs: Arlene Sharpe, Antonio Sica

- 4:30 – 4:55 pm **Arlene Sharpe** – Harvard Medical School (USA)
Overcoming microbiome-related resistance to PD-1/PD-L1 cancer immunotherapy
- 4:55 – 5:20 pm **Paola Nisticò** – IFO Regina Elena National Cancer Institute (Italy)
hMENA isoforms as architects of lung tumor immune microenvironment and determinants of immunotherapy response
- 5:20 – 5:45 pm **Alessandra Castiglioni** – Genentech (USA)
Anti-PD-L1 + anti-TGF β combination therapy expands stem cell-like CD8 T cells in immune-excluded tumors
- 5:45 – 6:00 pm **Lucas Blanchard*** – Rockefeller University (USA)
Overcoming the inhibitory FCYRIIB barrier unlocks FC-dependent activity of human anti-CTLA-4 antibodies



CRI-ENCI-AACR Seventh International Cancer Immunotherapy Conference

TRANSLATING SCIENCE INTO SURVIVAL

Sept. 20-23, 2023 | Milano, Italy

- 6:00 – 6:15 pm **Jyh Liang Hor *** – National Institutes of Health (USA)
PD-1/CDC1 axis regulates stem-like CD8+ T cell differentiation in the tumor draining lymph node
- 6:15 – 6:30 pm **Mike Curran*** – MD Anderson Cancer Center (USA)
Cytotoxic PD-L1/PL-L2 dual-specific antibodies effectively treat both immune “hot” and “cold” cancers


**Short talk from proffered abstract*

Organising Secretariat

Achelois - Professional Congress Organiser – Milano, IT


Phone +39.02.26432454

info@cancerimmunotherapyconference.org - www.cancerimmunotherapyconference.org



Day 4 – Saturday, September 23, 2023

- 8:30 – 10.40 pm** **Session 7: Bang on target: modulating the microbiota to improve cancer immunotherapy**
Chairs: Laurence Zitvogel, Matteo Bellone
- 8:30 – 8:55 am **Florenzia McAllister** – MD Anderson Cancer Center (USA)
Tumor resident microbes influencing immune responses
- 8:55 – 9:20 am **Laurence Zitvogel** – Gustave Roussy Cancer Campus (France)
Microbiota-dependent emigration of enterotropic T cells to tumors
- 9:20 – 9:45 am **Kathy McCoy** – University of Calgary (Canada)
Identifying microbes and metabolites that modulate cancer immunotherapy to translate discovery to treatment
- 9:45 – 10:10 am **Matteo Bellone** – IRCCS San Raffaele Hospital (Italy)
Impact of diet and microbiota on immunotherapy for plasma cell dyscrasias
- 10:10 – 10:25 am **Martina Molgora*** – Washington University School of Medicine (USA)
Lack of TREM2 during anti-PD1 therapy reprograms intestinal macrophages and microbiota to enhance tumor rejection
- 10:25 – 10:40 am **Vincent Rosa*** – Columbia University (USA)
Engineered probiotics direct the antigen-specificity of CAR-T cells in situ for broad tumor targeting
- 10:40 – 11:10** **Break**
- 11:10 – 1:20 pm** **Session 8: Cellular therapies: arming immune cells**
Chairs: Giulia Casorati, Anna Mondino
- 11:00 – 11:25 am **George Coukos** – University of Lausanne (Switzerland)
TIL therapy opportunities for solid tumors
- 11:25 – 11:50 am **Cassian Yee** – University of Texas (USA)
TCR-based Tumor Agnostic Cell Therapy
- 11:50 – 12:15 pm **Chiara Bonini** – Vita-Salute San Raffaele University (Italy)
Multiple genome editing for cancer immunotherapy with engineered lymphocytes
- 12:15 – 12:40 pm **Gianpietro Dotti** – University of North Carolina Lineberger Comprehensive Cancer Center (USA)
CAR-T cells next generation



CRI-ENCI-AACR Seventh International Cancer Immunotherapy Conference

TRANSLATING SCIENCE INTO SURVIVAL

Sept. 20-23, 2023 | Milano, Italy

- 12:40 – 1:05 am **Max Topp** - University of Würzburg (Germany)
TBD
- 1:05 – 1:20 pm **Lakshmi Balagopalan*** – National Cancer Institute (USA)
Generation of novel anti-tumor chimeric antigen receptors incorporating T cell signaling proteins
- 1:20 – 2:00 pm** **AACR Keynote Lecture**
Toni Ribas - UCLA (USA)
How Does PD-1 Blockade Immunotherapy for Melanoma Work?
- 2:00 pm** **Closing remarks and meeting ends**
Pier Francesco Ferrucci

**Short talk from proffered abstract*

Organising Secretariat

Achelois - Professional Congress Organiser – Milano, IT

Phone +39.02.26432454

info@cancerimmunotherapyconference.org - www.cancerimmunotherapyconference.org